



Join the race to

# 2030

*Supporting advocates in the race to defeat meningitis*

## Gavi's investment opportunity and what it means for meningitis

### Protecting Our Future - Investment Opportunity 2026 - 2030

Gavi, the Vaccine Alliance is a global health partnership that aims to support governments in lower-income countries to strengthen their healthcare systems and improve access to life-saving vaccines.

**Gavi is responsible for vaccinating more than half the world's children.** For more information on how the partnership works and what it has achieved [read this explainer](#).

In June 2024, Gavi launched its [Investment Opportunity](#) (IO) for 2026-2030. This explainer offers a brief overview of the document and what it means for meningitis.



#### What is Gavi's 2026–2030 Investment Opportunity?

Gavi's Investment Opportunity (IO) sets out the partnership's goals for the next five years and the funding required to achieve them. It is a call to action for Gavi's funders (e.g., governments, private organisations and individuals).

By 2030, Gavi intends to immunise at least 500 million more children. This has the potential to save more than 8 million lives. To achieve this, Gavi wants to raise \$9 billion USD through a "replenishment" process. This is a period of fundraising which will end in pledges from funders across the world.

#### What Gavi vaccines prevent meningitis?

Gavi supports countries to vaccinate against several causes of meningitis. Including, *Neisseria meningitidis* (Nm), *Haemophilus influenzae* type b (Hib) and *Streptococcus pneumoniae*.

The [Gavi Board meeting in July 2024](#) also included an 'approval in principle' to support the development of a vaccine for group B *Streptococcus* (GBS), as part of its [Vaccine Investment Strategy](#).



#### What does Gavi hope to achieve by 2030?

- **Ensure more children receive life-saving vaccines.** A key goal for Gavi is to reduce the number of "zero-dose" children (who have never received a vaccine) by 50%, in line with the Immunization Agenda 2030 (IA2030) goal (p.22).
- **Protect against more diseases.** Gavi plans to expand its vaccine portfolio by one-third, ultimately protecting against 24 diseases. In the next strategic period this includes the introduction of a tuberculosis (TB) vaccine (p. 15). TB meningitis occurs when tuberculosis bacteria invade the membranes and fluid surrounding the brain and spinal cord.
- **Build global resilience.** Gavi commits to making its largest ever investment in vaccine programmes and stockpiles for outbreak prone diseases, such as meningitis (p.9). The multivalent meningococcal conjugate vaccine (Men5), [already successfully used in Nigeria](#), will be included.
- **Foster strong partnerships.** Gavi states its commitment to collaborating with a broad range of partners, all with the aim of supporting countries to achieve their own priorities. This includes public health organisations, Africa Centres for Disease Control and Prevention (Africa CDC) and private companies (p.25).
- In the 2026–2030 period, Gavi has said it will intensify its work to ensure **vaccine markets** serve the best interests of low- and middle-income countries; it is aiming to reduce the price of vaccines and maintain a focus on supply security (p.33).
- Encourage private sector **investment in immunization** (The Gavi Matching Fund). This includes the development of refrigerated vaccine transport vehicles and drones to deliver vaccines to hard-to-reach places. (pg.37)



## What does Gavi hope to achieve by 2030?

*Continued...*

- Immunisation alone will not defeat meningitis. In the IO, Gavi commits to **integrating its work within countries' healthcare systems** (p.21), as well as global health **security infrastructure** (p.12). The partnership also recognises the important link between **climate change** and disease (p.9), as well as the challenge presented by **anti-microbial resistance** (p.11).



## How does this link with WHO's Global Road Map to Defeat Meningitis?

All four of the 'priority pathogens' in WHO's *Global Road Map to Defeat Meningitis by 2030* are included within Gavi's plans for the next five years.

The partnership is a key actor in the delivery of the Road Map's first three pillars (prevention and epidemic control, diagnosis and treatment and disease surveillance).

## African Vaccine Manufacturing Accelerator (AVMA):

0.1% of the world's vaccines are produced in Africa. To boost vaccine manufacturing on the continent, Gavi has created the AVMA (p.13). Pneumococcal and Hib vaccines are priorities for this initiative, which will be important for meningitis prevention.



## What is the price tag for this work?

**To achieve its goals, Gavi has said it will need 11.9 billion USD.** 2.9 billion USD has already been secured and 9 billion more needs to be raised (p. 42).

Gavi intends to spend 56% of the total \$11.9 billion on vaccines – both maintaining current programmes and expanding them to include new vaccines. The remaining 44% will be spent on strengthening systems and operational costs (p. 41, figure 14).



## Further reading:

- [Gavi's Investment Opportunity 2026–2030](#)
- [Blog: Gavi's Investment Opportunity by numbers](#)
- [Blog: Five years to save 8 million lives: everything you need to know about Gavi's Investment Opportunity](#)



## What happens next?

A [number of commitments and partnerships have already been confirmed](#). But, from now until the end of 2024, Gavi's partners (including governments and the private sector) will be invited to pledge their support and financial contributions.

Details on the date and location for a pledging conference are yet to be confirmed.

## Join the Race to 2030

Are you a civil society organisation or activist who is passionate about seeing meningitis defeated?

**Stay informed and join the Race to 2030 movement.**

**Find out more [here](#).**

#DefeatMeningitis  
meningitis.org

Notes: This explainer has been created by Meningitis Research Foundation and sets out our current understanding of Gavi's Investment Opportunity. This guide has been created for CoMO members and other civil society organisations to support activists around the world in engaging with and advocating for the vision of the WHO Global Road Map to Defeat Meningitis by 2030.